A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports DOI Creative Commons
Mona Sadat Larijani, Delaram Doroud,

Mohammad Banifazl

et al.

European journal of medical research, Journal Year: 2023, Volume and Issue: 28(1)

Published: Nov. 26, 2023

Abstract There have been massive studies to develop an effective vaccine against SARS-CoV-2 which fortunately led manage the recent pandemic, COVID-19. According quite rapidly developed vaccines in a fast window time, large investigations assess probable vaccine-related adverse events are crucially required. COVID-19 available of different platforms and primary clinical trials results presented acceptable safety profile approved vaccines. Nevertheless, long-term assessment or rare conditions need be investigated. The present systematic review, aimed at classification unsolicited Iranian population through data collection published case report studies. related reports were explored via PubMed, Web Science Google scholar according up 14 th Dec, 2022 using PRISMA guideline. Out 437 studies, relevant fully investigated totally 40 including 64 with new onset problem post-vaccination. cases then classified various items, such as type event reported studied included BBIBP-CorV, ChAdOx1-S, Sputnik V COVAXIN. showed that 8 categories, cutaneous involvements 43.7% ( n = 28), neurologic problems 16), blood/vessel involvement 6), cardiovascular 5), ocular disorders 4), liver disorder/failure 2), graft rejection 2) one metabolic disorder. Notably, almost 60% had no comorbidities. Moreover, obtained revealed nearly half incidences occurred after first dose injection median duration improvement symptom was 10 days (range: 2–120). In addition, 73% all either significantly improved recovered. Liver failure following ChAdOx1-S vaccination most serious death two individuals medical history. Although advantages is undoubtedly significant, history disease, comorbidities immunodeficiency should vaccinated utmost caution. This study provides comprehensive overview implications possible considered further strategies. there might bias regarding potential under-reporting missing study. not proven direct outcomes could immune response over stimulation, people medium/high risk monitored getting any platforms. achieved by carefull attention subjects ‘ also consulting healthcare providers before vaccination.

Language: Английский

Pyoderma Gangrenosum: Treatment Options DOI Creative Commons
Joachim Dissemond, Angelo Valerio Marzano, Philip Hampton

et al.

Drugs, Journal Year: 2023, Volume and Issue: 83(14), P. 1255 - 1267

Published: Aug. 23, 2023

Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although exact pathogenesis not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite limited understanding pathogenesis, it no longer diagnosis exclusion, as can now be made on basis validated scoring systems. However, therapy remains major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for treatment affected patients. In addition, concomitant topical pharmacologic therapy, wound management pain control should always addressed. Corticosteroids and/or cyclosporine remain systemic therapeutics choice most in recent years, there has an increasing number studies positive effects biologic such inhibitors tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics become drug certain scenarios, particularly patients underlying inflammatory comorbidities, increasingly used at early stage disease rather than refractory

Language: Английский

Citations

44
Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis DOI
Angelo Valerio Marzano, Carlo Alberto Maronese, Giovanni Genovese

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2022, Volume and Issue: 149(4), P. 1137 - 1149

Published: April 1, 2022

Language: Английский

Citations

47
Cutaneous manifestations following COVID‐19 vaccination: A report of 25 cases DOI
Safoura Shakoei, Yasamin Kalantari, Maryam Nasimi

et al.

Dermatologic Therapy, Journal Year: 2022, Volume and Issue: 35(8)

Published: June 18, 2022

Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented tertiary center skin following injection from September December 2021. All manifestation within 30 days or less vaccination were enrolled case-series. cases included diagnosed based on clinical and/or histopathological evaluation and other possible differential diagnoses ruled out. Twenty-five individuals including 16 (64%) males 9 (36%) females the mean age 47 ± 17.62 years (range 18-91) study. Twenty-two (88%) developed lesions after Sinopharm vaccine 3 (12%) manifested AstraZeneca vaccine. Six (24%) new-onset lichen planus (LP) 1 (4%) patient LP flare-up. Two (8%) psoriasis case showed exacerbation. One pemphigus vulgaris (PV) experienced a flare PV lesions. pityriasis lichenoides et varioliformis acuta (PLEVA) Other as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) 2, 8%), alopecia areata (AA) pytriasis rosea herpes zoster small vessel vasculitis erythema multiform (EM) urticaria 3, 12%), morphea 4%). Physicians should be aware side especially vaccines.

Language: Английский

Citations

47
Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis DOI Creative Commons
Chanudda Washrawirul, Jidapa Triwatcharikorn, Jeerath Phannajit

et al.

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2022, Volume and Issue: 36(11), P. 1947 - 1968

Published: June 6, 2022

Although vaccination is widely accepted as an effective method of preventing and controlling the COVID-19 pandemic, many people are concerned about possible cutaneous side-effects, which can delay or prevent them from being vaccinated. The objectives this systematic review were to assess global prevalence clinical manifestations adverse reactions following vaccination. PubMed Scopus databases searched for articles published 1 January 2019 31 December 2021, reference lists each selected article screened. Case reports, case series, observational studies randomized controlled trials that provided information on vaccines included. A total 300 included in a 32 with 946 366 participants meta-analysis. pooled was 3.8% (95% CI, 2.7%-5.3%). based mRNA platform had higher than other platforms at 6.9% 3.8%-12.3%). Various have been reported injection site reactions, most common (72.16%) uncommon such delayed inflammatory tissue filler (0.07%) flares pre-existing dermatoses (0.07%). Severe anaphylaxis also reported, but rare cases (0.05%). In conclusion, common, especially those receiving vaccines. Most mild not contraindications subsequent except anaphylaxis, rarely occurs. may be associated filler. Patients history allergies, skin conditions scheduled injections should receive additional precounselling monitoring. better understanding potential side-effects strengthen public confidence wary new vaccine technologies.

Language: Английский

Citations

39
Cutaneous manifestations of COVID‐19 and COVID‐19 vaccination DOI Creative Commons
Chisa Nakashima,

Maiko Kato,

Atsushi Otsuka

et al.

The Journal of Dermatology, Journal Year: 2023, Volume and Issue: 50(3), P. 280 - 289

Published: Jan. 13, 2023

In December 2019, a new infectious pathogen named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China. Transmitted through droplets, SARS-CoV-2 is the causative of disease 2019 (COVID-19). Although this COVID-19 infection known to cause primarily interstitial pneumonia and failure, it often associated with cutaneous manifestations as well. These can be classified into seven categories: (i) chilblain-like skin eruption (e.g., COVID toes), (ii) urticaria-like eruption, (iii) maculopapular lesions, (iv) vesicular eruptions, (v) purpura, (vi) livedo reticularis necrotic (vii) urticarial vasculitis, others such alopecia herpes zoster. The pathogenesis eruptions broadly divided vasculitic inflammatory eruptions. Various adverse reactions have also been observed after mRNA vaccination. major are type I hypersensitivity (urticaria anaphylaxis) IV (COVID arm erythema multiform). Autoimmune-mediated including bullous pemphigus, vitiligo, areata reported. Several cases lesions zoster vaccination published. diseases reported, mechanism has partly elucidated. process, for example, some papers reported that not related infection, although initially called COVID-toe considered COVID-19-associated eruption. fact, indistinguishable from drug future, mechanisms COVID-19- or vaccine-associated need elucidated verification causal relationships required.

Language: Английский

Citations

35
Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters DOI Creative Commons
Emmanouil Karampinis, Myrto-Maria Papadopoulou,

Kleoniki Chaidaki

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(2), P. 178 - 178

Published: Feb. 9, 2024

The diverse patient population and widespread vaccination in the COVD-19 era make vaccine-triggered episodes of psoriasis an ideal model exposome research. This scenario explores fine balance between protective exacerbating factors, providing insights into complex relationship environmental exposure immunopathogenesis when a trigger appears, such as that hyperinflammatory state induced by COVID-19 vaccine. Analyzing interactions vaccine-induced phenomena parameters may provide clinically relevant information important for personalized medicine decision-making. We performed literature review seeking patients with plaque flares or new onset change another subtype, pustular erythrodermic flare, focusing on inner external traits patients. identified 71 flares, 12 new-onset psoriasis, 17 subtype change, assessed terms clinical presentation, post-vaccination flare period treatment status, well (genomics, oxidative stress, hormonal impact due to gender, aging, skin color) (UV, infectomics). Novel data following are primarily obtained combining episode features characteristics comparing them similar unrelated vaccination.

Language: Английский

Citations

13
New‐onset lichen planus arising after COVID‐19 vaccination DOI

Orlando Zagaria,

Alessia Villani, Angelo Ruggiero

et al.

Dermatologic Therapy, Journal Year: 2022, Volume and Issue: 35(5)

Published: Feb. 11, 2022

Language: Английский

Citations

30
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era DOI Creative Commons

Ganggang Miao,

Zhiqiang Chen,

Hengsong Cao

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 158, P. 114208 - 114208

Published: Jan. 2, 2023

The COVID-19 pandemic has affected millions of people and posed an unprecedented burden on healthcare systems economies worldwide since the outbreak COVID-19. A considerable number nations have investigated proposed a series prevention treatment strategies thus far. implemented in China suggested that spread can be effectively reduced by restricting large-scale gathering, developing community-scale nucleic acid testing, conducting epidemiological investigations, whereas sporadic cases always been identified numerous places. Currently, there is still no decisive therapy for or related complications. development vaccines raised hope mitigating this based intercross immunity induced Thus far, several types developed released to into financial markets. From perspective vaccine use globe, are beneficial mitigate pandemic, relative adverse events reported progressively. This review about development, challenges prospects vaccines, it provide more insights all aspects vaccines.

Language: Английский

Citations

17
Bullous pemphigoid after SARS‐CoV‐2 vaccination: spike‐protein‐directed immunofluorescence confocal microscopy and T‐cell‐receptor studies DOI Open Access
Thilo Gambichler, Nazha Hamdani,

Heidi Budde

et al.

British Journal of Dermatology, Journal Year: 2021, Volume and Issue: 186(4), P. 728 - 731

Published: Nov. 13, 2021

Journal Article Bullous pemphigoid after SARS‐CoV‐2 vaccination: spike‐protein‐directed immunofluorescence confocal microscopy and T‐cell‐receptor studies Get access T. Gambichler, Gambichler Department of Dermatology Ruhr‐University Bochum Germany https://orcid.org/0000-0001-7862-3695 Search for other works by this author on: Oxford Academic Google Scholar N. Hamdani, Hamdani Institut für Forschung und Lehre (IFL) Molecular Experimental Cardiology GermanyDepartment St Josef‐Hospital GermanyInstitute Physiology H. Budde, Budde M. Sieme, Sieme Skrygan, Skrygan L. Scholl, Scholl Dickel, Dickel B. Behle, Behle Ganjuur, Ganjuur C. Scheel, Scheel ... Show more Abu Rached, Rached Ocker, Ocker R. Stranzenbach, Stranzenbach Doerler, Doerler Pfeiffer, Pfeiffer Translational Skin Cancer Research DKTK Partner Site Essen/Düsseldorf West German Center University Duisburg‐Essen Essen GermanyGerman (DKFZ) Heidelberg https://orcid.org/0000-0003-3729-2249 J.C. Becker https://orcid.org/0000-0001-9183-653X British Dermatology, Volume 186, Issue 4, 1 April 2022, Pages 728–731, https://doi.org/10.1111/bjd.20890 Published: 01 2022

Language: Английский

Citations

35
COVID-19 disease and autoimmune disorders: A mutual pathway DOI
Mohammed Al‐Beltagi, Nermin Kamal Saeed, Adel Salah Bediwy

et al.

World Journal of Methodology, Journal Year: 2022, Volume and Issue: 12(4), P. 200 - 223

Published: July 14, 2022

Coronavirus disease 2019 (COVID-19) is a real challenge for humanity with high morbidity and mortality. Despite being primarily respiratory illness, COVID-19 can affect nearly every human body tissue, causing many diseases. After viral infection, the immune system recognize antigens presented by cells. This response usually controlled terminated once infection aborted. Nevertheless, in some patients, reaction becomes out of control development autoimmune Several tissue showed strong antibodies directed against severe acute syndrome coronavirus 2 (SARS-CoV-2) proteins, such as SARS-CoV-2 S, N, target proteins. The immunogenic effects are due to sizeable RNA molecules interrupted transcription increasing pool epitopes increased chances molecular mimicry interaction host system, overlap between peptides, induced-tissue damage, robust complex binding sACE-2 S protein. Consequently, its vaccine may trigger diseases predisposed patient. review discusses mutual relation diseases, their interactive on each other, role triggering factors affecting severity patients suffering from different ways minimize risk

Language: Английский

Citations

27